Advances in Neuropharmacology and Brain Injury Therapeutics

Dear Colleagues,

This Special Issue of Pharmaceuticals is focused on exploring the current advancements in therapies for neurodegenerative diseases and brain injuries, highlighting the latest research and potential future directions for clinical practice.

The landscape of neuropharmacology and brain injury therapeutics is changing rapidly, with an increasing focus on addressing the fundamental mechanisms involved in injury and recovery. Rather than merely treating symptoms, current research and clinical approaches seek to target the complex and dynamic pathophysiology underlying secondary brain injuries, including neuroinflammation, oxidative stress, and disruption of the blood–brain barrier (BBB). Notable innovations in the field include the use of nanomedicine for targeted drug delivery, the application of stem cell therapies for tissue regeneration, and the adoption of precision medicine to tailor treatments based on individual biomarkers and genetic profiles.

The main categories of recent therapeutic advances in neurodegenerative diseases and brain injuries are outlined below:

1. Neuropharmacological Advances and Drug Discovery

Recent efforts in neuropharmacology are centred on the development of neuroprotective agents that go beyond symptom management, aiming to limit secondary brain damage and actively support neural recovery. Examples of emerging drug strategies include the following:

• Inhibiting excitotoxicity, which involves the excessive activation of neurons leading to cell death, thereby preserving neural function.
• Reducing oxidative stress, a process in which free radicals cause damage to neural cells and tissues.
• Modulating neuroinflammatory pathways, such as targeting the Stimulator of Interferon Genes (STING) pathway. This approach, utilising small-molecule inhibitors, has shown promise in dampening the inflammatory response after brain injury and improving patient outcomes.

2. Nanomedicine and Targeted Delivery

Nanotechnology is playing an increasingly important role in the delivery of therapies for brain injuries. Key advancements include the following:

• The engineering of nanoparticles and nanocarriers capable of crossing the BBB, which has historically posed a significant barrier to effective treatment of brain disorders.
• The use of these carriers to deliver therapeutic agents directly to the site of injury, enhancing drug efficacy while minimising potential side effects.
• Examples of such nanocarriers include liposomes, dendrimers, and polymeric nanoparticles, which can be loaded with neuroprotective or anti-inflammatory drugs to support recovery.

3. Stem Cell and Regenerative Therapies

Regenerative medicine, particularly stem cell-based therapies, is at the forefront of new treatments for brain injuries. Areas of current exploration include the following:

• The investigation of utilising exogenous and endogenous stem cells for their ability to repair damaged neural tissue.
• The potential of these cells to differentiate into neurons and glial cells, thus replacing cells lost or damaged due to injury.
• The role of stem cells in secreting factors that help modulate the immune response, reduce inflammation, and promote tissue repair and recovery.

4. Technological Interventions for Rehabilitation

Innovative technological approaches are transforming rehabilitation for individuals with brain injuries. These include the following:

• The integration of robotics, virtual reality, and brain–computer interfaces into therapy programmes to support motor and cognitive recovery.
• The provision of personalised, adaptive training and real-time feedback using these technologies, which can accelerate patient progress and improve outcomes.

5. Precision Medicine and Diagnostic Biomarkers

The adoption of precision medicine is leading to more effective and individualised treatment strategies. Key developments involve the following:

• The use of diagnostic biomarkers, such as specific proteins and genetic markers, to classify brain injuries and more accurately predict patient prognosis.
• The tailoring of treatments according to an individual’s genetic and molecular profile, thereby increasing the likelihood of therapeutic success.
• The identification of patient subgroups most likely to benefit from particular interventions, supporting a more targeted and efficient approach to care.

Despite these significant advancements, translating therapies from preclinical studies to successful clinical applications remains challenging. Factors such as the heterogeneity of brain injuries, difficulties in crossing the BBB, and the lack of standardised clinical trial protocols continue to impede progress in the field. The aim of this Special Issue of Pharmaceuticals is to highlight cutting-edge research addressing these challenges and to define future directions in the treatment of neurodegenerative diseases and brain injury.

Dr. Bruce X.W. Wong
Dr. Kaelyn Tan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• neurodegenerative diseases
• brain injuries
• nanomedicine and targeted delivery
• stem cell and regenerative therapies
• precision medicine and diagnostic biomarkers